ClinicalTrials.gg
RecruitingNCT05861050Updated Oct 26, 2026

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

A Phase 1/2 interventional study of Biopsy and Biospecimen Collection in Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma and Pleomorphic Variant Mantle Cell Lymphoma, sponsored by City of Hope Medical Center. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by City of Hope Medical Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing glofitamab in Lymphoma, Mantle-Cell — 11 open to participants now, 12 under way, none of them phase 3. glofitamab · Lymphoma, Mantle-Cell.

Planned enrollment
3rd of 13
50 · median 40
Started
2023
with 1 other
Phase 1/2
2 of 13
2 open now
Primary completion
2027-02
later than 0 of 11 live
Registered
3rd of 13
by date
Lead sponsor
2 of 13
City of Hope Medical Center

Among the 13 studies testing glofitamab in Lymphoma, Mantle-Cell, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 2 in phase 1/2, reaches primary completion later than 0 of the 11 other live ones, and was the 3rd registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

11 of the 13 studies testing glofitamab in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About glofitamab

glofitamab: first FDA approval 2023 (COLUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing glofitamab in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving venetoclax, glofitamab with obinutuzumab, and lenalidomide together may kill more cancer cells in patients with newly diagnosed, high risk mantle cell lymphoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of venetoclax, glofitamab and lenalidomide in newly diagnosed patients with high risk mantle cell lymphoma (MCL) as measured by progression free survival (PFS) at 24 months.

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of the combination of lenalidomide, venetoclax and glofitamab in patients with newly diagnosed MCL.

II. To determine overall response rate (ORR) of patients with newly diagnosed MCL who are treated with the combination of lenalidomide, venetoclax and glofitamab.

III. To determine the complete remission rate of the combination in patients with untreated MCL.

IV. To determine the PFS at 24 months of the patients with p53 mutation versus (vs.) those who lack this abnormality.

V. To determine duration of response of patients treated with the combination lenalidomide, venetoclax and glofitamab.

VI. To determine progression free survival of patients who obtain minimal residual disease (MRD) negativity.

EXPLORATORY OBJECTIVES:

I. To evaluate changes in T-cell repertoire at baseline and on treatment based on exposure to glofitamab utilizing immune-sequence (seq) assay.

II. To determine if any other baseline genetic feature impacts response and/or duration of response to the treatment regimen.

III. To evaluate outcomes of treated patients based on segregation into distinct MCL clusters using whole exome sequencing (WES).

IV. To determine if rates of cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) are impacted by co-administration of lenalidomide/venetoclax in conjunction with glofitamab.

V. To determine if utilization and efficacy of tocilizumab for CRS is impacted by co-administration of lenalidomide/venetoclax in conjunction with glofitamab.

OUTLINE:

Patients receive venetoclax orally (PO), obinutuzumab intravenously (IV), glofitamab IV, and lenalidomide IV on study. Patients undergo bone marrow biopsy, blood sample collection, and computed tomography (CT) scan and/or positron emission tomography (PET) scan throughout the study. Patients may undergo tumor biopsy throughout the study.

Patients are followed-up every 3 months for the first two years, and then every 6 months starting in the third year until disease recurrence.

03

Conditions studied

  • Blastoid Variant Mantle Cell Lymphoma
  • Mantle Cell Lymphoma
  • Pleomorphic Variant Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: >= 18 to 80 years
  • =\< 2
  • Diagnosis of MCL established by histologic assessment including one of the following:

    • Immunohistochemistry of the biopsy
    • Flow cytometry of the biopsy
  • Evidence of t(11;14) translocation involving the cyclin D1 gene by fluorescence in situ hybridization (FISH), and/or cyclin D1 expression by immunohistochemistry (IHC) unless disease is morphologically consistent with MCL and has IHC expression of SOX11
  • Requiring treatment for MCL, and for which no prior systemic anticancer therapies have been received

    • Local radiotherapy not exceeding a total dose of 20 Gy at least 2 weeks prior the first dose of study therapy is allowed
  • Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL

    • Asymptomatic patients with blastoid or pleomorphic variant can be enrolled
  • High risk features as classified by Jain et al.

    • Blastoid/pleomorphic variants
    • Ki67 >= 50%
    • Presence of a TP53 mutation defined by either molecular testing or IHC
    • del (17p) by FISH
    • Complex karyotype
    • High-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score (>= 6.2)
    • Bulky disease
    • The presence of other high risk gene mutations (KMT2D, NSD2, NOTCH1, CDKN2A, NOTCH2, SMARCA4, CCND1) as long one of the other features above are present
  • Ability to swallow oral capsules/tablets
  • Without bone marrow involvement: (ANC) >= 1,000/mm\^3 With bone marrow involvement: ANC >= 500/mm\^3

    • NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
  • Without bone marrow involvement: >= 75,000/mm\^3 With bone marrow involvement: Platelets >= 25,000/mm\^3

    • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
  • Without bone marrow involvement: >= 8 g/dL With bone marrow involvement: Hemoglobin >= 7 g/dL

    • NOTE: Red Blood cells transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement
  • Total =\< 1.5 x (ULN) (unless has Gilbert's disease)
  • (AST) =\< 3.0 x ULN
  • Alanine aminotransferase (ALT) =\< 3.0 x ULN
  • of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula
  • If not receiving anticoagulants: (INR) OR prothrombin (PT) =\< 1.5 x ULN If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
  • If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\< 1.5 x ULN If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
  • Women of (WOCBP): negative serum pregnancy test
  • Agreement by females and males of childbearing potential to use an effective method of (i.e., failure rate of \< 1% per year) or abstain from heterosexual activity for the course of the study treatment period through at least 30 days after the last dose of venetoclax and lenalidomide, 18 months after the last dose of obinutuzumab, 2 months after the last dose of glofitamab, or 4 months after the last dose of tocilizumab (if applicable) whichever is longer

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

      • All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS) (registered trademark) program and be willing and able to comply with the requirements of the REMS (registered trademark) program (including use of aspirin [ASA]/ Food and Drug Administration [FDA] approved blood thinner)
      • Females of must adhere to the scheduled pregnancy testing as required in the Revlimid REMS (registered trademark) program

Exclusion criteria

Exclusion Criteria:

  • Treatment with the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)
  • Treatment with strong or moderate inhibitors or strong CYP3A inducers within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug. Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to first dose of venetoclax
  • Ongoing use > 30 mg/day of prednisone or equivalent. Patients who received corticosteroid treatment with =\< 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to day 1 of cycle 1. Patients may have received a brief (=\< 7 days) course of systemic steroids (>= 100 mg prednisone equivalent per day) prior to initiation of study therapy for control of lymphoma-related symptoms

    • Corticosteroid therapy for control of cancer symptoms is permitted
    • The use of inhaled corticosteroids is permitted
    • The use of mineralocorticoids for management of orthostatic hypotension is permitted
    • The use of physiologic doses of corticosteroids for management of adrenal insufficiency is permitted
  • Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Prior solid organ transplantation within 60 months and requiring active
  • Receipt of live-virus vaccine within 28 days prior to the initiation of the study treatment or need for live-virus vaccines at any time during the study treatment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents
  • History of other that could affect compliance with the protocol or interpretation of results

    • Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible
    • Patients with low-grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to study are eligible
    • Patients with any other malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for >= 2 years prior to enrollment are eligible
    • Patients receiving endocrine therapy for non-, hormone receptor positive breast cancer for >= 2 years prior to enrollment are eligible
  • Major surgery (within 4 weeks prior to the start of the first dose of study treatment), other than for diagnosis
  • Known or suspected chronic active Epstein-Barr viral infection
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • Known history of progressive multifocal leukoencephalopathy
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Known allergy to both xanthine oxidase inhibitors and rasburicase
  • Positive for virus (HCV) virus by polymerase chain reaction (PCR) at screening. Testing only required if the hepatitis (Hep) C antibody is positive
  • Positive test results for virus (HBV) infection (defined as positive surface antigen [HBsAg]) at screening

    • Patients with occult or prior HBV infection (defined as negative HBsAg and positive hepatitis B core antibody [HBcAb]) may be included if HBV deoxyribonucleic acid (DNA) is undetectable, if they are willing to undergo DNA testing on day 1 of every cycle and every three months for at least 12 months after the last cycle of study treatment and appropriate antiviral therapy
  • Known active (HIV) infection. Subjects who have an undetectable or unquantifiable HIV viral load with > 200 and are on highly active antiretroviral therapy (HAART) medication are allowed. Testing to be done only in patients suspected of having infections or exposures
  • Significant or extensive cardiovascular disease such has class III or IV cardiac disease or Objective Assessment class C or D, myocardial infarction within the last 6 months, unstable arrythmias or unstable angina
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment
  • Suspected or latent tuberculosis (confirmed by positive interferon -gamma release assay)
  • Females only: Pregnant or breastfeeding or intending to become pregnant during the study or within 18 months after the final dose of all study drugs

    • Women of must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
  • History of uncontrolled condition or disease requiring active systemic treatment to manage except when on a stable regimen for the treatment of hypothyroidism, Type 1 diabetes mellitus or psoriasis/eczema (topicals only)

    • Patients with history of immune thrombocytopenic purpura, autoimmune hemolytic anemia, Guillain-Barre syndrome, myasthenia gravis, myositis, rheumatoid arthritis, vasculitis, or other autoimmune disease will be excluded unless they have not required systemic therapy in the last 12 months
    • Prior treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 4 weeks prior to first dose of study treatment
    • Patients with a history of autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease with active symptoms within last 60 months and on active immunosuppressive therapy, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjogren syndrome, multiple sclerosis, or glomerulonephritis will be excluded
  • Primary or secondary central nervous system (CNS) lymphoma at the time of recruitment or history of CNS lymphoma
  • Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease

    • Patients with a history of stroke who have not experienced a stroke or within the past 9 months and have no residual neurologic deficits, as judged by the investigator, are allowed
  • history of cirrhotic liver disease
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment (venetoclax, glofitamab, lenalidomide)

    Patients receive venetoclax PO, obinutuzumab IV, glofitamab IV, and lenalidomide IV on study. Patients undergo bone marrow biopsy, blood sample collection, and CT scan and/or PET scan throughout the study. Patients may undergo tumor biopsy throughout the study.

    Procedure: Biopsy · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Biological: Glofitamab · Drug: Lenalidomide · Biological: Obinutuzumab · Procedure: Positron Emission Tomography · Drug: Venetoclax

Interventions

  • ProcedureBiopsy

    Undergo tumor biopsy

    Also known as: BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography

  • BiologicalGlofitamab

    Given IV

    Also known as: Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859

  • Given PO

    Also known as: CC-5013, CC5013, CDC 501, Revlimid

  • BiologicalObinutuzumab

    Given IV

    Also known as: Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT

  • Given PO

    Also known as: ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Time frame: From first dose of combination lenalidomide, venetoclax, and glofitamab to the occurrence of definitive disease progression or death from any cause, assessed up to 24 months

  2. Incidence of dose limiting toxicity

    Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 63 days after initiation of venetoclax

Secondary outcomes

  1. Incidence of adverse events of special interest

    Adverse events of special interest including neurotoxicity, cytopenias, and infections are graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Cytokine release syndrome is graded according to American Society for Transplantation and Cellular Therapy criteria.

    Time frame: From baseline up until 30 days after last dose of study drug

  2. Median (or mean) PFS

    Time frame: From the first dose of the combination of lenalidomide, venetoclax, and glofitamab to the occurrence of definitive disease progression or death from any cause, whichever comes first, assessed up to 5 years

  3. Best overall response

    Determined by revised Lugano 2016 criteria. Includes complete response and partial response.

    Time frame: Until disease progression or at 1 year after initiating therapy, whichever is sooner

  4. Minimal residual disease status

    Time frame: At the end of 12 cycles of treatment (each cycle is 28 days)

  5. Duration of response

    Time frame: From the time of initial response until disease progression or death due to any cause, whichever occurs first, assessed up to 2 years

07

Study locations

3 of 3 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.

Of 51 non-industry phase 1/2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 78 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 122. This study's planned 41 months is below that.

Counting every sponsor, half of 77 studies reached it within 75 months; a quarter within 45 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 16, 2023
StartActual
Aug 10, 2023
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 26, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • City of Hope Medical Center · Duarte, United Statesno status→Recruiting
  • Mount Sinai School of Medicine · New York, United Statesno status→Recruiting
  • Huntsman Cancer Institute · Salt Lake City, United Statesno status→Recruiting
Oct 26, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • City of Hope Medical Center · Duarte, United StatesContact added t•••@coh.org · •••2405Contact added (no phone or email listed)
  • Mount Sinai School of Medicine · New York, United StatesContact added J•••@mssm.edu · •••8557
  • Huntsman Cancer Institute · Salt Lake City, United StatesContact added D•••@hci.utah.edu · •••7000
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • City of Hope Medical Center · Duarte, United Statesno status→Recruiting
    • Mount Sinai School of Medicine · New York, United Statesno status→Recruiting
    • Huntsman Cancer Institute · Salt Lake City, United Statesno status→Recruiting
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • City of Hope Medical Center · Duarte, United StatesContact added t•••@coh.org · •••2405Contact added (no phone or email listed)
    • Mount Sinai School of Medicine · New York, United StatesContact added J•••@mssm.edu · •••8557
    • Huntsman Cancer Institute · Salt Lake City, United StatesContact added D•••@hci.utah.edu · •••7000
  2. Oct 16, 2026
    Why stopped 10/12/2026 DSMC: Resuming suspension instated on 09/18/2026 due to unresolved monitoring findings, study accrual is suspended and will remain on hold until reportable events identified in IMV are reported.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05861050
Responsible party
Sponsor
First posted
May 16, 2023
Start date
Aug 10, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Tycel J Phillips
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glofitamab · Lenalidomide · Obinutuzumab · Venetoclax

Start the discussion